Plain-English translation of NCT06683950 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial examined whether —a higher dose of a medication injected into the eye—could help patients whose vision was not improving with their current eye injections. Participants had been receiving either faricimab or aflibercept 2mg but still had fluid in the back of their eye, a sign that the treatment wasn't working as well as hoped. The study tested whether switching to this new, stronger dose might give better results.
Some patients with age-related macular degeneration continue to have fluid buildup in the eye even after receiving regular injections of current medications. Researchers wanted to find out if a higher dose of this medication could help these patients achieve better vision and clearer eye scans when standard treatments weren't enough.
Participants received eye injections of the new medication dose over the course of the study period. They attended regular clinic visits for eye exams, imaging scans to measure fluid in the eye, and vision testing to track how well the treatment was working. The study lasted approximately 76 weeks, during which participants had multiple follow-up appointments to monitor their response to the new medication and watch for any side effects.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
South Korea